1. Home
  2. FMST vs SCLX Comparison

FMST vs SCLX Comparison

Compare FMST & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Foremost Lithium Resource & Technology Ltd.

FMST

Foremost Lithium Resource & Technology Ltd.

N/A

Current Price

$0.72

Market Cap

10.9M

ML Signal

N/A

Logo Scilex Holding Company

SCLX

Scilex Holding Company

N/A

Current Price

$1.62

Market Cap

12.0M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FMST
SCLX
Founded
2005
2011
Country
Canada
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.9M
12.0M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
FMST
SCLX
Price
$0.72
$1.62
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 269.3K
32.1K
Earning Date
11-24-2026
11-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $30,253,000.00
Revenue This Year
N/A
$118.16
Revenue Next Year
N/A
$186.31
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.42
$1.61
52 Week High
$3.49
$27.00

Technical Indicators

Market Signals
Indicator
FMST
SCLX
Relative Strength Index (RSI) 54.43 16.70
Support Level $0.45 N/A
Resistance Level $0.90 $7.77
Average True Range (ATR) 0.09 0.17
MACD 0.03 0.05
Stochastic Oscillator 58.75 3.45

Price Performance

Historical Comparison
FMST
SCLX

About FMST Foremost Lithium Resource & Technology Ltd.

Foremost Clean Energy Ltd is an exploration company focused on the identification and development of high potential mineral opportunities in stable jurisdictions. Its Uranium properties includes Eastern Athabasca, and Blue-Sky. Its Lithium properties includes Zoro Lithium Project, JEAN LAKE LITHIUM GOLD PROJECT, Peg North Project, Grass River Claims Project, and JOL LITHIUM PROJECT.

About SCLX Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. It targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes. Its commercial products are: ZTlidoO for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a potential first-line treatment ready-to-use oral solution for the acute treatment of migraine in adults and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.

Share on Social Networks: